Cardiovascular health and mortality in Cushing's disease.


Journal

Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578

Informations de publication

Date de publication:
Oct 2022
Historique:
accepted: 08 07 2022
pubmed: 23 7 2022
medline: 26 10 2022
entrez: 22 7 2022
Statut: ppublish

Résumé

Exposure to cortisol excess in Cushing's disease (CD) results in increased cardiovascular morbidity and reduces survival, with cardiovascular disease being a leading cause of death. At diagnosis, a significant number of patients have adverse cardiovascular profiles (e.g., obesity, diabetes or impaired glucose tolerance, dyslipidemia, hypertension, cardiac abnormalities and vascular disease). Remission of hypercortisolemia reduces but does not completely eliminate the cardiovascular complications; hazard ratios for myocardial infarction and stroke are high during long-term monitoring, highlighting the long-lasting effects of hypercortisolism and the importance of the timely diagnosis and successful management of this condition. Data on mortality of patients in remission are not consistent but in a multicenter study, an increased all-cause and circulatory mortality in patients with CD in remission for at least 10 years has been demonstrated. Cardiovascular morbidity requires particular focus and effective management during the care of patients with CD, from their presentation until long-term follow up.

Identifiants

pubmed: 35869339
doi: 10.1007/s11102-022-01258-4
pii: 10.1007/s11102-022-01258-4
pmc: PMC9587928
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

750-753

Informations de copyright

© 2022. Crown.

Références

Clin Endocrinol (Oxf). 2012 Mar;76(3):332-8
pubmed: 21854405
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2375-2384
pubmed: 30715394
Clin Endocrinol (Oxf). 2011 Sep;75(3):354-60
pubmed: 21521323
J Clin Endocrinol Metab. 2012 Apr;97(4):1194-201
pubmed: 22278423
J Clin Endocrinol Metab. 2012 May;97(5):1702-11
pubmed: 22419708
Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875
pubmed: 34687601
J Clin Endocrinol Metab. 2013 Jun;98(6):2277-84
pubmed: 23533241
Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101521
pubmed: 33766428
Eur J Endocrinol. 2013 Oct 08;169(5):715-23
pubmed: 23996696
Clin Endocrinol (Oxf). 2010 Oct;73(4):469-75
pubmed: 20550536
Neuroendocrinology. 2010;92 Suppl 1:44-9
pubmed: 20829617
Eur J Endocrinol. 2021 Apr 22;184(5):R207-R224
pubmed: 33539319
Lancet Diabetes Endocrinol. 2016 Jul;4(7):569-76
pubmed: 27265184
J Clin Endocrinol Metab. 1999 Aug;84(8):2664-72
pubmed: 10443657
J Clin Endocrinol Metab. 2014 Nov;99(11):E2144-53
pubmed: 25093618
Neuroendocrinology. 2010;92 Suppl 1:86-90
pubmed: 20829625
J Clin Endocrinol Metab. 2003 Jun;88(6):2527-33
pubmed: 12788849

Auteurs

Amy Coulden (A)

Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Ross Hamblin (R)

Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

John Wass (J)

Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Niki Karavitaki (N)

Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. n.karavitaki@bham.ac.uk.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK. n.karavitaki@bham.ac.uk.
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. n.karavitaki@bham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH